Corient Private Wealth
RLMD icon

Corient Private Wealth’s Relmada Therapeutics RLMD Stock Holding History

Corient Private Wealth’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-719,582
Closed -$4.96M – 3206
2026
Q1 		$4.96M Hold
719,582
– – 0.01% 844
2025
Q4 		$3.44M Buy
719,582
+512,915
+248% +$1.72M ﹤0.01% 910
2025
Q3 		$402K Hold
206,667
– – ﹤0.01% 1935
2025
Q2 		$120K Buy
+206,667
New +$106K ﹤0.01% 2308

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Corient Private Wealth's RLMD Position: Q2 2026 in Review

Corient Private Wealth sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 719,582 shares — an estimated $4.96M sold.

Corient Private Wealth first reported a position in RLMD in Q2 2025 and held it in 4 quarters. The position peaked at $4.96M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Corient Private Wealth reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Corient Private Wealth sold 719,582 Relmada Therapeutics shares in Q2 2026, an estimated $4.96M.
  • Corient Private Wealth first reported a position in Relmada Therapeutics in Q2 2025 and held it in 4 quarters.
  • Corient Private Wealth's Relmada Therapeutics position peaked at $4.96M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.